Case study of a severe drug-induced liver injury caused by paliperidone in a patient after liver transplantation

Published on Aug. 31, 2023Total Views: 1808 times Total Downloads: 763 times Download Mobile

Author: Wei-Peng ZHANG ^1, ²  Sa-Sa HU ¹

Affiliation: 1. Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China 2. Department of Pharmacy, The Xi'an Eighth Hospital, Xi’an 710061, China

Keywords: Paliperidone Liver transplantation Liver injury Adverse drug reactions

DOI: 10.19960/j.issn.1005-0698.202310012

Reference: Wei-Peng ZHANG, Sa-Sa HU.Case study of a severe drug-induced liver injury caused by paliperidone in a patient after liver transplantation[J].Yaowu Liuxingbingxue Zazhi,2023, 32(10):1182-1187.DOI: 10.19960/j.issn.1005-0698.202310012.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Clinical pharmacists participated in the liver protection treatment in a patient after liver transplantation with severe liver injury (ALT 1 733 U·L^-1, AST 940 U·L^-1, AKP 703 U·L^-1). By medication analysis and used the RUCAM scale, pharmacist evaluate acute drug-related liver injury that may be due to high blood levels of paliperidone that caused by the drug interaction of paliperidone and fluconazole. By reviewing the literature and analyzing the possible mechanisms of paliperidone-induced liver injury combined with the characteristics of patient's laboratory examination, it was suggested that this drug should be stopped in time and liver protection treatment should be carried out. Finally, the patient's liver injury was significantly improved. In this case, the clinical pharmacist combined pharmaceutical knowledge and blood concentration monitoring results to give effective pharmaceutical therapy for the clinic, which fully reflects the value of the clinical pharmacists. This case can provide a certain reference for the severe liver injury caused by paliperidone.

Full-text

Please download the PDF version to read the full text: download

References

1.韦石凤, 马登磊, 李林, 等. 精神分裂症药物治疗研究进展[J]. 中国新药与临床杂志, 2023, 42(4): 209-215. [Wei XF, Ma DL, Li L, et al. Advances in drug therapy for schizophrenia[J]. Chinese Journal of New Drugs and Clinical Remedies, 2023, 42(4): 209-215.] DOI: 10.14109/j.cnki.xyylc.2023.04.01.

2.许世欢, 吴声辉. 帕利哌酮与利培酮治疗精神分裂症的临床效果比较[J]. 临床合理用药杂志, 2022, 15(23): 17-19, 23. [Xu SH, Wu SH. Comparison of the clinical effects of paliperidone and risperidone in the treatment of schizophrenia[J]. Chinese Journal of Clinical Rational Drug Use, 2022, 15(23): 17-19, 23.] DOI: 10.15887/j.cnki.13- 1389/r.2022.23.005.

3.Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017[J]. Pharmacopsychiatry, 2018, 51(1-02): 9-62. DOI: 10.1055/s-0043-116492.

4.Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone[J].Expert Rev Clin Phar, 2018, 11(6): 625-639. DOI: 10.1080/17512433.2018.1478727.

5.马明明, 路敏, 孔妍, 等. 丙戊酸钠治疗癫痫致患者药物性肝损伤的病例分析[J]. 中国临床药理学杂志, 2019, 35(23): 3101-3103. [Ma MM, Lu M, Kong Y, et al. Analysis of patients with drug-induced liver injury induced by epilepsy treated with sodium valproate[J]. Chinese Journal of Clinical Pharmacology, 2019, 35(23): 3101-3103.] DOI: 10.13699/j.cnki.1001-6821.2019.23.040.

6.韩玉珍, 王延庆, 黄立锋. 肝移植术后早期肝功能不全危险因素及防治的研究进展[J]. 医学研究生学报, 2021, 34(2): 185-189. [Han YZ, Wang YQ, Huang LF. Research progress on the risk factors and prevention of early allograft dysfunction after liver transplantation[J]. Journal of Medical Postgraduates, 2021, 34(2): 185-189.] DOI: 10.16571/j.cnki.1008-8199.2021.02.014.

7.于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 257-274. [Yu LC, Mao YM, Chen CW. Guidelines of drug-induced liver injury[J].Journal of Practical Hepatology, 2017, 20(2): 257-274.] DOI: 10.3969/j.issn.1672-5069.2017.02.039.

8.王直滔, 何玲芳, 楼永海. 1例培唑帕尼片致重度肝损伤的病例分析与药学监护[J]. 药物流行病学杂志, 2023, 32(1): 116-120. [Wang ZT, He LF, Lou YH. Pharmaceutical care and individualized selection of liver protective drugs in a case of severe liver injury caused by pezopanib tablets[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(1): 116-120.] DOI: 10.19960/j.issn.1005-0698.202301018.

9.Gunther M, Dopheide JA. Antipsychotic safety in liver disease: a narrative review and practical guide for the clinician[J]. J Acad Consult-liais, 2023, 64(1): 73-82. DOI: 10.1016/j.jaclp.2022.09.006.

10.Chang CH, Lane HY, Liu CY, et al. Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: a nationwide population-based cohort study[J]. Psychiat Res, 2019, 281: 112597. DOI: 10.1016/j.psychres.2019.112597.

11.袁婷, 钱灿, 宿怀予. 氟康唑氯化钠注射液致老年患者严重肝损伤1例[J]. 医学理论与实践, 2022, 35(4): 718-719. [Yuan T, Qian C, Su HY. Fluconazole sodium chloride injection caused severe liver injury in an elderly patient: a case report[J]. Journal of Medical Theory and Practice, 2022, 35(4): 718-719.] DOI: 10.19381/j.issn.1001-7585.2022.04.080.

12.中国老年医学研究会内分泌代谢分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国药物警戒, 2018, 15(10): 627-640. DOI: 1672-8629(2018)10-0627-14.

13.Hiemke C, Baumann P, Bergemann N, et al. AGNP Consensus Guidelines for therapeutic drug monitoring in psychiatry: update 2011[J]. Pharmacopsychiatry, 2011, 44(6): 195-235. DOI: 10.1055/s-0031-1286287.